EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluation of model‐integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods

Henrik Bjugård Nyberg iD, Xiaomei Chen iD, Mark Donnelly iD, Lanyan Fang iD, Liang Zhao iD, Mats O Karlsson iD, Andrew C Hooker iD

CPT: Pharmacometrics & Systems Pharmacology · 2024

DOI: 10.1002/psp4.13217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Henrik Bjugård Nyberg und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Therapeutic Equivalency, Models, Biological, Computer Simulation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Conventional approaches for establishing bioequivalence (BE) between test and reference formulations using non‐compartmental analysis (NCA) may demonstrate low power in pharmacokinetic (PK) studies with sparse sampling. In this case, model‐integrated evidence (MIE) approaches for BE assessment have been shown to increase power, but may suffer from selection bias problems if models are built on the same data used for BE assessment. This work presents model averaging methods for BE evaluation and compares the power and type I error of these methods to conventional BE approaches for simulated studies of oral and ophthalmic formulations. Two model averaging methods were examined: bootstrap model selection and weight‐based model averaging with parameter uncertainty from three different sources, either from a sandwich covariance matrix, a bootstrap, or from sampling importance resampling (SIR). The proposed approaches increased power compared with conventional NCA‐based BE approaches, especially for the ophthalmic formulation scenarios, and were simultaneously able to adequately control type I error. In the rich sampling scenario considered for oral formulation, the weight‐based model averaging method with SIR uncertainty provided controlled type I error, that was closest to the target of 5%. In sparse‐sampling designs, especially the single sample ophthalmic scenarios, the type I error was best controlled by the bootstrap model selection method.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Therapeutic EquivalencyModels, BiologicalComputer SimulationHumansAdministration, OralPharmacokineticsModels, Statistical

Autor:innen und Institutionen

  • Department of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Division of Quantitative Methods and Modelling, Office of Research and Standards, Office of Generic Drugs, Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Henrik Bjugård Nyberg, Xiaomei Chen, Mark Donnelly, Lanyan Fang, Liang Zhao, Mats O Karlsson, Andrew C Hooker

Zitieren

APA

Bjugård Nyberg, H., Chen, X., Donnelly, M., Fang, L., Zhao, L., Karlsson, M. O., & Hooker, A. C. (2024). Evaluation of model‐integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13217

Vancouver

Bjugård Nyberg H, Chen X, Donnelly M, Fang L, Zhao L, Karlsson MO, et al. Evaluation of model‐integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13217

BibTeX
@article{BjugrdNyberg2024,
  author = {Bjugård Nyberg, Henrik and Chen, Xiaomei and Donnelly, Mark and Fang, Lanyan and Zhao, Liang and Karlsson, Mats O and Hooker, Andrew C},
  title = {Evaluation of model‐integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  doi = {10.1002/psp4.13217}
}
Kostenlos starten →